Information Provided By:
Fly News Breaks for March 5, 2018
AIMT, DBVT
Mar 5, 2018 | 07:17 EDT
H.C. Wainwright analyst Andrew Fein spent time with "leading" key opinion leaders in food allergy at this year's American Academy of Allergy, Asthma and Immunology meeting to talk about the oral immunotherapy from Aimmune Therapeutics (AIMT) and epicutaneous immunotherapy from DBV Technologies (DBVT). Although there were positives viewed from both approaches, the KOLs believe that the stronger safety profile along with the convenience of the patch will generate more support for DBV from parents who wish to ensure that their children are not at risk of a life-threatening situation due to an accidental exposure to peanut protein, Fein tells investors in a research note. The analyst believes DBV's ViaSkin peanut patch provides a safe and effective means to increase peanut tolerance. He sees "very low risk" associated with the DBV program due to its "excellent" safety and tolerability profile. Secondly, it appears to generate at a level of efficacy that is sufficient to avoid accidental exposure, Fein tells investors. He adds the company appears to be in the enviable position of submitting its approval application to the FDA before Aimmune. Fein has a Buy rating on DVT and does not rate Aimmune.
News For DBVT;AIMT From the Last 2 Days
There are no results for your query DBVT;AIMT